Skip to main content

Table 2 Baseline characteristics

From: Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease

 

Lp(a) increased ( +) (n = 307)

Lp(a) increased (-) (n = 181)

p value

Age[years]

66.54 ± 9.49

64.85 ± 10.50

0.067

Male [cases (%)]

202 (65.80)

126 (69.61)

0.386

BMI (kg/m2)

24.08 ± 3.11

24.62 ± 3.12

0.067

Diabetes mellitus [cases (%)]

92 (26.97)

70 (38.67)

0.049

Hypertension [cases (%)]

229 (74.59)

137 (75.69)

0.787

Smoking history [cases (%)]

141 (45.93)

84 (46.41)

0.918

Family history [cases (%)]

28 (9.12)

12 (6.63)

0.333

Creatinine (μmoI/L)

87.91 ± 19.00

87.30 ± 17.12

0.726

hs-CRP (mg/L)

3.0 (1.0 – 25.0)

3.0 (1.0 – 5.0)

0.491

Angiography data

 Single-vessel lesiona [cases (%)]

100 (32.57)

48 (26.52)

0.160

 Double-vessel lesions [cases (%)]

79 (25.73)

55 (30.39)

0.266

 Triple-vessel lesions [cases (%)]

127 (41.37)

78 (43.09)

0.709

 Left main lesion [cases (%)]

27 (8.79)

21 (11.60)

0.314

 CTO [cases (%)]

61 (19.87)

37 (20.44)

0.879

 Coronary stents (number)

2.42 ± 1.53

2.53 ± 1.68

0.472

Baseline blood lipids

  

0.176

 TC (mmol/L)

4.43 ± 1.67

4.45 ± 1.03

0.849

 LDL-C (mmol/L)

2.57 ± 0.96

2.59 ± 0.82

0.820

 HDL-C (mmol/L)

1.09 ± 0.27

1.08 ± 0.28

0.759

 Lp(a) mg/dL

14.0 (8.0 – 29.0)

12.0 (7.0 – 22.0)

0.176

 TG (mmol/L)

1.68 ± 1.41

1.68 ± 1.00

0.999

On-statin blood lipids

 TC (mmol/L)

3.33 ± 0.73

3.31 ± 0.81

0.796

 LDL-C (mmol/L)

1.65 ± 0.57

1.67 ± 0.50

0.654

 HDL-C (mmol/L)

1.13 ± 1.00

1.01 ± 0.25

0.161

 Lp(a) mg/dL

20.7 (11.0 – 40.7)

10.0 (6.4 – 18.2)

 < 0.001

 TG (mmol/L)

1.31 ± 0.76

1.46 ± 0.78

0.031

Medicine use

 Statin [cases (%)]

307 (100.0)

181 (100.0)

—

 Ezetimibe [cases (%)]

16 (5.21)

15 (8.29)

0.178

 β blocker [cases (%)]

250 (81.43)

151 (83.43)

0.579

 ACEI/ARB [cases (%)]

221 (71.99)

139 (76.80)

0.243

Antiplatelet agent (at discharge)

 DAPT [cases (%)]

307 (100.0)

181 (100.0)

—

 Aspirin [cases (%)]

307 (100.0)

181 (100.0)

—

 Clopidogrel [cases (%)]

242 (78.83)

136 (75.14)

0.346

 Ticagrelor [cases (%)]

65 (21.17)

45 (28.86)

0.346

Antiplatelet agent (at the end of FUP)

 DAPT [cases (%)]

30 (9.77)

12 (6.63)

0.232

 SAPT [cases (%)]

277 (90.23)

169 (93.37)

0.232

 Aspirin [cases (%)]

268 (87.30)

162 (89.50)

0.467

 Clopidogrel [cases (%)]

61 (19.87)

28 (15.47)

0.224

 Ticagrelor [cases (%)]

8 (2.61)

3 (1.66)

0.495

  1. Lp(a) increased ( +): patients with on-statin Lp(a) levels higher than baseline Lp(a) levels
  2. Lp(a) increased (-): patients with on-statin Lp(a) levels less than or equal to baseline Lp(a) levels
  3. BMI body mass index, hs-CRP high sensitivity C-reactive protein, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglycerides, Lp(a) Lipoprotein (a), ACEI angiotensin converting enzyme inhibitor, ARB angiotensin-receptor blocker, DAPT dual antiplatelet therapy, SAPT single antiplatelet therapy, FUP follow up, CTO total coronary occlusion
  4. aLesion was defined as coronary artery diameter stenosis of more than 50%
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us